These findings underscore the critical need to develop effective management strategies, including dose modifications and granulocyte colony-stimulating factor use, tailored to individual patient needs among those receiving FTD/TPI plus ramucirumab therapy. This evidence concerns the gene CSF3 and frontotemporal dementia.